Coherus Will Prioritize Oncology As Inflammation Takes A Back Seat

Sandoz Enbrel Ruling Leads Company To Chop Asset

 
• By Dean Rudge
Invest
Coherus will invest R&D dollars into oncology and immuno-oncology • Source: Shutterstock

More from Biosimilars

More from Products